학술논문

From prediction to prevention: Machine learning revolutionizes hepatocellular carcinoma recurrence monitoring.
Document Type
Editorial & Opinion
Author
Ramírez-Mejía MM; Plan of Combined Studies in Medicine, Faculty of Medicine, National Autonomous University of Mexico, Distrito Federal 04510, Mexico.; Liver Research Unit, Medica Sur Clinic & Foundation, Distrito Federal 14050, Mexico.; Méndez-Sánchez N; Liver Research Unit, Medica Sur Clinic & Foundation, Distrito Federal 14050, Mexico.; Faculty of Medicine, National Autonomous University of Mexico, Distrito Federal 04510, Mexico. nah@unam.mx.
Source
Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 100883448 Publication Model: Print Cited Medium: Internet ISSN: 2219-2840 (Electronic) Linking ISSN: 10079327 NLM ISO Abbreviation: World J Gastroenterol Subsets: MEDLINE
Subject
Language
English
Abstract
In this editorial, we comment on the article by Zhang et al entitled Development of a machine learning-based model for predicting the risk of early postoperative recurrence of hepatocellular carcinoma . Hepatocellular carcinoma (HCC), which is characterized by high incidence and mortality rates, remains a major global health challenge primarily due to the critical issue of postoperative recurrence. Early recurrence, defined as recurrence that occurs within 2 years posttreatment, is linked to the hidden spread of the primary tumor and significantly impacts patient survival. Traditional predictive factors, including both patient- and treatment-related factors, have limited predictive ability with respect to HCC recurrence. The integration of machine learning algorithms is fueled by the exponential growth of computational power and has revolutionized HCC research. The study by Zhang et al demonstrated the use of a groundbreaking preoperative prediction model for early postoperative HCC recurrence. Chall-enges persist, including sample size constraints, issues with handling data, and the need for further validation and interpretability. This study emphasizes the need for collaborative efforts, multicenter studies and comparative analyses to validate and refine the model. Overcoming these challenges and exploring innovative approaches, such as multi-omics integration, will enhance personalized oncology care. This study marks a significant stride toward precise, effi-cient, and personalized oncology practices, thus offering hope for improved patient outcomes in the field of HCC treatment.
Competing Interests: Conflict-of-interest statement: All the authors declare that they have no conflicts of interest related to the manuscript.
(©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.)